4 Days
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
4 Daysالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
4 DaysReady to play
Ready to play
Researchers at the University of Colorado Anschutz recommended using teplizumab as an immunotherapy alongside insulin for children and adolescents recently diagnosed with type 1 diabetes. The aim is to preserve insulin-producing pancreatic cells and slow the decline in insulin production. The recommendations require confirmed autoantibodies, an age of 8 to 17, recovery from any medical emergencies, and starting treatment within eight weeks of diagnosis. They stress that teplizumab does not replace insulin, and that insulin doses should be adjusted based on actual blood glucose readings.
Notice: This Is an AI-Generated Summary
Comments (0)